Matthew T Wheeler
Overview
Explore the profile of Matthew T Wheeler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
4005
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ostrominski J, Claggett B, Jerosch-Herold M, Raja A, Day S, Russell M, et al.
JAMA Cardiol
. 2025 Mar;
PMID: 40042824
Importance: Valsartan has been shown to attenuate phenotypic progression among individuals with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Myocardial tissue characterization by cardiac magnetic resonance (CMR) imaging may enhance mechanistic insights,...
2.
Ormond K, Stanclift C, Reuter C, Carter J, Murphy K, Lindholm M, et al.
BMC Med Ethics
. 2025 Feb;
26(1):22.
PMID: 39920727
Background: There is growing consensus in favor of returning individual specific research results that are clinically actionable, valid, and reliable. However, deciding what and how research results should be returned...
3.
Santana E, Kim D, Christle J, Cauwenberghs N, Celestin B, Tso J, et al.
Eur J Prev Cardiol
. 2025 Feb;
PMID: 39920345
Aims: Cardiorespiratory fitness (CRF), measured by peak oxygen uptake (VO2peak), is a strong predictor of mortality. Despite its widespread clinical use, current reference equations for VO2peak show distorted calibration in...
4.
Kim D, Schuetz N, Johnson A, Tolas A, Mantena S, OSullivan J, et al.
Prog Cardiovasc Dis
. 2025 Jan;
PMID: 39884325
Background: The six-minute walk test (6MWT) is a prognostic sub-maximal exercise test used clinically as a measure of functional capacity. With the emergence of advanced sensors, 6MWTs are being performed...
5.
Arriaga M, Mendez R, Ungar R, Bonner D, Matalon D, Lemire G, et al.
medRxiv
. 2025 Jan;
PMID: 39802771
RNA-sequencing has improved the diagnostic yield of individuals with rare diseases. Current analyses predominantly focus on identifying outliers in single genes that can be attributed to cis-acting variants within the...
6.
Dawood M, Heavner B, Wheeler M, Ungar R, LoTempio J, Wiel L, et al.
ArXiv
. 2025 Jan;
PMID: 39764392
Rare diseases are collectively common, affecting approximately one in twenty individuals worldwide. In recent years, rapid progress has been made in rare disease diagnostics due to advances in DNA sequencing,...
7.
Jordan E, Ni H, Parker P, Kinnamon D, Owens A, Lowes B, et al.
medRxiv
. 2024 Dec;
PMID: 39649582
Background: Clinical genetic evaluation of dilated cardiomyopathy (DCM) is implemented variably or not at all. Identifying needs and barriers to genetic evaluations will enable strategies to enhance precision medicine care....
8.
Meisner J, Renberg A, Smith E, Tsan Y, Elder B, Bullard A, et al.
Circulation
. 2024 Dec;
PMID: 39633578
Background: Classically, hypertrophic cardiomyopathy (HCM) has been viewed as a single-gene (monogenic) disease caused by pathogenic variants in sarcomere genes. Pathogenic sarcomere variants are individually rare and convey high risk...
9.
Tan Q, McConkie-Rosell A, Mahoney R, Spillmann R, Schoch K, Chanprasert S, et al.
Am J Med Genet A
. 2024 Dec;
197(4):e63956.
PMID: 39629753
Patients with undiagnosed and/or rare disorders frequently manifest dysmorphic and neurological features. There is a lack of information on the effectiveness of telehealth in the evaluation of these disorders. We...
10.
Kim D, Chu E, Keamy-Minor E, Paranjpe I, Tang W, OSullivan J, et al.
Front Cardiovasc Med
. 2024 Sep;
11:1429230.
PMID: 39314763
Mavacamten is a first-in-class cardiac myosin ATPase inhibitor, approved by the United States Food and Drug Administration for the treatment of hypertrophic cardiomyopathy with obstructive physiology (oHCM). Here, we present...